Accelerated Biosciences and Pluristyx Announce Availability of Human Trophoblast Stem Cell (hTSC) Derived iPSCs
Accelerated Biosciences, a regenerative medicine innovator of proprietary human trophoblast stem cells (hTSCs), announced an agreement for Pluristyx, Inc., an advanced therapy tools and services biotechnology company, to provide iPSCs derived from hTSCs procured under Good Tissue Practices (GTP) for research evaluation.
Finding the ideal source of stem cells remains a challenge in cell and gene therapy. hTSCs overcome these challenges as they are ethically sourced, scalable, immune-privileged, pathogen-free, and chromosomally stable even at high population doublings. As Accelerated Biosciences’ CDMO partner, Pluristyx reprogrammed hTSCs to iPSCs with a footprint-free, proprietary mRNA method that yields highly pure stem cells with demonstrated capacity to form all three tissue types, including terminal differentiation into NK cells with superior cytolytic activity. hTSC-iPSCs are available in Pluristyx’s unique Ready-to-Differentiate® format (RTD®), allowing for rapid evaluation by eliminating the need for expansion out of thaw. Because hTSC-iPSCs are sourced under GTP, commercial partners can transition to a clinical-grade version when appropriate.
“We are thrilled to present our hTSC-iPSC platform as a new starting cell source for therapeutic companies. Our platform provides all of the business advantages and reduced risks. Clinical grade hTSC-iPSCs will be available in 2023 with a complete regulatory support package,” said Yuta Lee, Chief Executive Officer of Accelerated Biosciences.
“Pluristyx is excited to offer iPSCs derived from Accelerated Biosciences’ unique hTSC starting material. These iPSCs robustly form differentiated cells from all three lineages and are derived under GTP and they are not associated with any living human or embryo, making them an exceptional starting material for next generation cell-based therapies. Available in our RTD® format, interested groups can accelerate their internal evaluation and rapidly transition to a clinical-grade version suitable for therapeutic manufacturing,” said Benjamin Fryer, Chief Executive Officer of Pluristyx.
About Accelerated Biosciences
Accelerated Biosciences is a private regenerative medicine company commercializing the hTSC platform, discovered by physician and researcher, Professor Jau-Nan Lee, MB, MD, PhD. Accelerated Biosciences holds a proprietary source of hTSCs with a robust intellectual property estate. Accelerated Biosciences’ mission is to leverage its renewable, immune-privileged human cell source to accelerate cures to patients and to make gene and cell therapy affordable to all in need. For more information about Accelerated Biosciences, visit www.acceleratedbio.com or email firstname.lastname@example.org.
Pluristyx is a privately held biotechnology company offering consulting, wet-lab and GMP banking services, and pluripotent stem cell products to support novel therapeutic developers. Pluristyx helps industry and academic researchers solve manufacturing and analytical challenges in cryopreservation, drug development, regenerative medicine, and cell and gene therapy. The Pluristyx team has decades of experience supporting every stage of cell therapy product development, from cell banking to drug product manufacturing including analytical testing and release of clinical grade cell therapy products. For more information about Pluristyx, visit www.pluristyx.com or email Kaye Reiter, PhD, JD at email@example.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Biognosys Announces Appointment of Beat Lüthi, Ph.D., as independent Board Director19.5.2022 14:00:00 CEST | Press release
Biognosys, a leader in next-generation proteomics solutions for life science research and drug development, announced today the appointment of Beat Lüthi, Ph.D., as Board Director. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220519005079/en/ Beat Lüthi, Ph.D. – Biognosys' Newly Appointed Board Director. (Photo: Business Wire) Dr. Lüthi is Chief Executive Officer of CTC Analytics AG, a privately owned Swiss company leading in automation and advanced laboratory sample handling solutions for the pharmaceutical, life science, chemical, environmental, and food & flavor industries. Additionally, he holds several Board of Directors mandates in public firms, including Chairman of Inficon Group, Vice Chairman of Straumann Group, and Board Member of Skan AG. Dr. Lüthi holds an M.Sc. in Electrical Engineering and a Ph.D. in Business Administration from ETH Zurich and completed an International Executive Program at the INSEAD Busines
Inversago Pharma Presents Data on INV-202 in Diabetic Nephropathy at the ERA 2022 Congress19.5.2022 14:00:00 CEST | Press release
Inversago Pharma Inc. (“Inversago”), a clinical stage biotech company with a unique portfolio of CB1 inverse agonists, announces the presentation of preclinical data at the 59th Congress of the European Renal Association (ERA), the largest annual nephrology meeting in Europe, currently held in Paris, France. These data show that INV-202, the company’s lead peripheral CB1 blocker, reduced renal injury in a murine model of Streptozotocin (STZ)-induced Diabetes. More specifically, INV-202 reduced glomerular injury, renal fibrosis and injury to proximal tubular epithelial cells, and also preserved podocyte structure and function. In particular, there was a marked, dose-dependent reduction in albuminuria in this model of diabetes and associated kidney injury. “The study showed that treatment with INV-202 reduced the progression of nephropathy in STZ-induced diabetic mice. Improvements in kidney size, function, and renal matrix remodeling, with corresponding gene expression were noted with b
Grovara Partners with Dubai Global Connect, Establishes Middle East HQ and Showroom19.5.2022 13:00:00 CEST | Press release
Grovara, the easy global wholesale experience, announces it has signed a lease agreement and become formally incorporated to do business in Dubai as part of a partnership with Dubai Global Connect (DGC), a permanent wholesale market that facilitates business between international buyers and sellers. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220519005017/en/ Grovara and Dubai Global Connect cemented their partnership on April 26, 2022 at DGC's new Visitor Centre in Dubai. Standing, from left are Grovara Sales Director Eugenia Schlitter, Grovara Executive Chairman David Pottruck, Grovara Chief Innovation Officer/Co-founder Peter Groverman, Dubai Global Connect Food Business Development Lead Badreddine Soukarie, and Grovara VP of Global Supply Chain Juliana Rogenski; Seated, from left are Dubai Global Connect Head of Business Development Paul Boots and Grovara CEO/Co-founder Abu Kamara. (Photo: Business Wire) The partnersh
Zilliant Launches Quick Start Program to Speed Time to Value and First Quick Start Package, Transforming How Companies Manage Pricing in Response to Inflation19.5.2022 13:00:00 CEST | Press release
Zilliant, the industry leader in intelligent end-to-end pricing solutions and sales guidance software, today announced its Zilliant Quick Start Program, which enables significantly faster deployment times for its software and faster time-to-value for customers. The first Quick Start package of this transformative program is Zilliant Quick Start for Global and Country Price Lists, which is available beginning today. In the past, deploying price optimization and management software may have seemed time intensive or difficult to implement. As a direct result, pricing and commercial teams rely on spreadsheets to manage pricing, sales operations and commercial functions, a method that is insufficient to respond to today’s volatile market conditions. The Zilliant Quick Start program flips this paradigm, offering packaged solutions to address specific pricing and sales challenges, each of which can be up and running within the span of three to eight weeks, work seamlessly with each other on t
Eaton Introduces DC-DC Converters for 48-Volt Commercial Vehicle Architectures19.5.2022 12:30:00 CEST | Press release
Power management company Eaton today introduced a family of 48-volt DC-DC converters for diesel-powered commercial vehicles that can be used to power accessories such as antilock brakes and lighting. Unlike competitive offerings, Eaton’s DC-DC converters are operational in ambient temperatures up to 85 degrees Celsius and boast 97% design efficiency. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220519005093/en/ Eaton’s family of 48-volt DC-DC converters can be used to power accessories such as antilock brakes and lighting and are operational in ambient temperatures up to 85 degrees Celsius. (Graphic: Business Wire) “DC-DC converters are an essential part of our eMobility product portfolio and are used in a variety of vehicle applications,” said Ben Karrer, director, Technology Development, Eaton’s eMobility business. “Many commercial vehicle manufacturers are transitioning to 48-volt architectures, so having the ability to
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom